Delivery Order SPE2DB22D3010-SPE2DB24FP1TN

Award Date 2/20/24
Potential Completion Date 2/21/24
Potential Value $8.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $8,233.01, is for the delivery of Valsartan-HCTZ 320-25 mg tablets in quantities of 90. This is a firm fixed-price delivery order contract with an ultimate completion date of March 5, 2024. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $6,492.05, is for the delivery of Valsartan-HCTZ 320-25 mg tablets in 90-count containers. The contract is a firm fixed-price delivery order with no set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award, valued at $1,548.56, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Valsartan-HCTZ 320-12.5 mg tablets in 90-count packages. It is a firm-fixed-price delivery order contract with a completion date of November 8, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,073.09, is for the delivery of Valsartan-HCTZ 320-25 mg tablets in 90-count packages. This is a firm-fixed price delivery order contract with a completion date of May 9, 2024. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a larger...
This is a federal contract award issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $6,685.31, is for the delivery of Valsartan-HCTZ 320-25 mg tablets in 90-count packages. This is a Firm Fixed Price Delivery Order contract with a completion date of February 16, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract, worth $6,359.76, is for the delivery of Valsartan-HCTZ 160-25 mg tablets in 90-count packages. The contract has a completion date of May 15, 2024 and is a firm fixed-price delivery order. This award is not set aside for any specific business type. AmerisourceBergen holds a significant $999,999,999...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,424.26 firm fixed-price delivery order is for the supply of Valsartan-HCTZ 320-25 mg tablets. The contract has an ultimate completion date of February 20, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $8,220.05, is for the delivery of Valsartan-HCTZ 160-12.5 mg tablets in 90-count packages. The contract has a firm fixed price structure and a period of performance ending on May 16, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award, valued at $7,323.65, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Valsartan-HCTZ 320-25 mg tablets in 90-count bottles. It is a firm-fixed-price delivery order contract with a completion date of July 15, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract, valued at $1,857.43, is for the delivery of Valsartan-HCTZ 160-12.5 mg tablets over a period ending on June 13, 2024. The contract is a Firm Fixed Price Delivery Order and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC)...
  • SPE2DB22D3010
    Indefinite Delivery Contract
  • SPE2DB22D3010-SPE2DB24FP1TN
    Delivery Order

This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $8,280.72, is for the delivery of Valsartan-HCTZ 320-25 mg tablets in a 90 count package. This is a Firm Fixed Price Delivery Order contract with a completion date of February 21, 2024.

AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies.

The contract award reviewed does not have a set-aside designation, indicating open competition.

Generated 5/14/25, 10:30 AM